Actinium reports ATNM-400 cancer therapy data at AACR meeting Apr 22, 2026 07:01AM
Actinium presents breast cancer data for ATNM-400 at medical conference Dec 12, 2025 08:45AM
Nvidia CEO says China market opportunity about $50 billion if able to compete Aug 27, 2025 05:50PM
Baidu and Uber partner to deploy autonomous vehicles globally Jul 15, 2025 08:02AM
Actinium Pharma (ATNM) Highlights Expanded Data Set for ATNM-400 Jun 23, 2025 11:31AM


Apr 28, 2025 08:36AM Actinium Pharma (ATNM) Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models
Mar 17, 2025 08:50AM Actinium Pharma (ATNM) Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Mar 11, 2025 08:34AM Actinium Pharma (ATNM) Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly
Jul 25, 2024 08:45AM Actinium Pharma (ATNM) Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients